Portolan Capital Management LLC Has $72.70 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Portolan Capital Management LLC boosted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 812,630 shares of the medical equipment provider's stock after acquiring an additional 141,749 shares during the period. Lantheus accounts for about 4.9% of Portolan Capital Management LLC's holdings, making the stock its biggest position. Portolan Capital Management LLC owned approximately 1.17% of Lantheus worth $72,698,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D boosted its holdings in shares of Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after acquiring an additional 115 shares in the last quarter. Bleakley Financial Group LLC increased its holdings in Lantheus by 6.1% in the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after buying an additional 129 shares in the last quarter. Avantax Advisory Services Inc. increased its stake in Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after purchasing an additional 132 shares in the last quarter. Foundry Partners LLC raised its holdings in Lantheus by 4.5% during the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock worth $278,000 after purchasing an additional 133 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on LNTH shares. Truist Financial increased their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. B. Riley dropped their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, JMP Securities restated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $129.43.

Insider Activity

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock valued at $6,016,046 in the last three months. Corporate insiders own 1.50% of the company's stock.

Lantheus Stock Up 0.8 %

Shares of NASDAQ:LNTH traded up $0.80 during midday trading on Friday, reaching $101.32. The company's stock had a trading volume of 430,521 shares, compared to its average volume of 954,003. Lantheus Holdings, Inc. has a 1 year low of $61.47 and a 1 year high of $126.89. The business has a 50 day moving average price of $95.00 and a 200 day moving average price of $95.55. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of 16.86 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.